Transcenta Holding Limited

Equities

6628

KYG9005B1041

Pharmaceuticals

Delayed Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
2.08 HKD -0.95% Intraday chart for Transcenta Holding Limited +1.96% -42.06%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcenta Holding Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcenta Publishes Promising Results of Anti-Tumor Drug's Efficacy and Safety in European Journal MT
Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging CI
Transcenta Presents Data on Gastric/Gastroesophageal Cancer Treatment Trial at Spain Oncology Meet MT
Transcenta Holding Limited Presents Updated Efficacy Data from the Expansion Cohort of the Transtar102 of Osemitamab Plus Capox Chemotherapy Study as the First-Line Treatment of Advanced G/Gej Cancer At the ESMO Congress 2023 in Madrid, Spain CI
US FDA Approves Phase 3 Trial for Transcenta's Gastric Cancer Treatment MT
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients CI
Transcenta Widens Loss in H1 MT
Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023 CI
Transcenta Holding Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Transcenta Moves to Phase II Trial of Osteoporosis Drug MT
Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab) CI
China, South Korea Approve Transcenta's Phase 3 Trial for Anti-Tumor Medication MT
Transcenta Holding Limited Receives Approval from China CDE and South Korea MFDS to Initiate Transtar301 Global Phase III Pivotal Trial of Osemitamab CI
Transcenta Holding Limited Presents Pfs Data by Cldn18.2 Expression Level from Phase I/Ii Study of Osemitamab Plus Capecitabine and Oxaliplatin as the First-Line Treatment of Advanced G/Gej Cancer CI
Transcenta Holding Limited Announces Update on Efficacy Data of Osemitamab Plus Capecitabine and Oxaliplatin CI
Transcenta Holding Limited commences an Equity Buyback for 10% of its issued share capital, under the authorization approved on June 9, 2023. CI
Transcenta Holding Limited's Equity Buyback announced on September 14, 2022, has expired. CI
Transcenta Presents Data on Gastric Cancer Treatment at US Oncology Meeting MT
Transcenta Holding Limited Presents Updated Data of Cohort C from Phase I/IIa, Multi-Center Study of Osemitamab CI
Transcenta's Phase I Study of Reduced Bone Mineral Density Treatment Shows Encouraging Results MT
Transcenta Holding Limited Announces Encouraging Phase I Clinical Data of TST002 in Chinese Patients with Reduced Bone Mineral Density CI
Transcenta to Present Clinical Trial Progress of Osemitamab MT
Transcenta Holding Limited to Present Two Clinical Trial Progress At Asco 2023 CI
Transcenta Completes Enrollment of Patients for Phase II Study of Gastric Cancer Treatment MT
Chart Transcenta Holding Limited
More charts
Transcenta Holding Limited is a China-based investment holding company engaged in the discovery, research, development, manufacturing and business development of biopharmaceuticals in the clinical stage. The Company's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The Company's all products are in the research and development (R&D) stage and have not been commercialized. The Company also provides contract developmentand manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.921 CNY
Average target price
7.58 CNY
Spread / Average Target
+294.63%
Consensus